How Common Is Anaphylaxis Following Vaccination?
To investigate the incidence of anaphylaxis after vaccination, study authors reviewed data submitted to the Vaccine Adverse Event Reporting System (VAERS) between 1990 and 2016.
All articles by Da Hee Han
FDA to Review Tafamidis for Treatment of Transthyretin Amyloid Cardiomyopathy
Tafamidis is an oral small molecule candidate that selectively binds at specific sites on the transthyretin tetramer to prevent destabilization of the transthyretin transport protein and formation of amyloid that causes ATTR-CM.
Caplacizumab Cuts Time to Platelet Count Normalization in aTTP Patients
The HERCULES (NCT02553317) study included 145 patients with aTTP who were randomized to receive either caplacizumab 10mg or placebo in conjunction with plasma exchange and immunosuppression.
Glass Particulate Identified in Certain Vials of Vecuronium Bromide
Vecuronium Bromide, a neuromuscular blocker, is indicated as adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
reSET-O Digital Therapeutic for Opioid Use Disorder Now Available
Sandoz and Pear Therapeutics announced the launch of reSET-O, a new digital therapeutic for patients aged ≥18 years with opioid use disorder (OUD) currently under clinician care.
FDA-Approved Wearable Blood Pressure Monitor Now Available
HeartGuide is designed as a wrist watch that uses the oscillometric cuff method, the standard for medical-grade personal blood pressure measurement.
Lonafarnib Gets Breakthrough Tx Designation for Progeria, Progeroid Laminopathies
There is currently no approved treatment for progeria, an ultra-rare and rapidly fatal genetic condition that causes accelerated aging in children.
Prevalence of Benzodiazepine Use, Misuse Among US Adults Analyzed
Alprazolam was found to be the most commonly misused benzodiazepine.
First Digital Inhaler With Built-In Sensors Gets FDA Approval
ProAir Digihaler is the first digital inhaler with built-in sensors that connects to a mobile application and provides data on inhaler use to patients with asthma and chronic obstructive pulmonary disease (COPD).
Prescription Digital Therapeutic Approved for Opioid Use Disorder
reSET-O is intended for use as an adjunct to outpatient treatment that includes transmucosal buprenorphine (medication-assisted-treatment [MAT]) and contingency management for patients aged ≥18 years who are currently under clinician supervision.
- Loading...
Loading...
Next post in Tech Talk
Loading... 
Loading...